Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Interest Expenses (2016 - 2025)

Ocular Therapeutix has reported Interest Expenses over the past 13 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Interest Expenses at $2.8 million for Q4 2025, down 8.82% from a year ago — trailing twelve months through Dec 2025 was $11.8 million (down 12.84% YoY), and the annual figure for FY2025 was $11.8 million, down 12.83%.
  • Interest Expenses for Q4 2025 was $2.8 million at Ocular Therapeutix, down from $3.0 million in the prior quarter.
  • Over the last five years, Interest Expenses for OCUL hit a ceiling of $4.2 million in Q4 2023 and a floor of $1.7 million in Q2 2021.
  • Median Interest Expenses over the past 5 years was $2.4 million (2023), compared with a mean of $2.5 million.
  • Biggest five-year swings in Interest Expenses: surged 129.13% in 2024 and later decreased 26.34% in 2025.
  • Ocular Therapeutix's Interest Expenses stood at $1.7 million in 2021, then increased by 9.94% to $1.8 million in 2022, then skyrocketed by 124.74% to $4.2 million in 2023, then decreased by 25.17% to $3.1 million in 2024, then decreased by 8.82% to $2.8 million in 2025.
  • The last three reported values for Interest Expenses were $2.8 million (Q4 2025), $3.0 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.